Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs [Yahoo! Finance]
Cocrystal Pharma, Inc. (COCP)
NASDAQ:AMEX Investor Relations:
cocrystalpharma.com
Company Research
Source: Yahoo! Finance
Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance influenza A/B replication inhibitor program BOTHELL, Wash., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “We expect to begin enrolling participants in the first quarter of 2026 for our norovirus challenge study evaluating CDI-988 , our oral broad-spectrum protease inhibitor,” said Sam Lee, Ph.D., President and co-CEO of Cocrystal. “This study will provide an initial assessment of CDI-988 for both prevention and treatment of norovirus infection. Norovirus is a major cause of acute gastroenteritis and is highly contagious. It spreads rapidly in enclosed environments such as cruise ships, military bases, nursing homes, and hospitals. At p
Show less
Read more
Impact Snapshot
Event Time:
COCP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COCP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COCP alerts
High impacting Cocrystal Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
COCP
News
- Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference [Yahoo! Finance]Yahoo! Finance
- Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity ConferenceGlobeNewswire
- Cocrystal Pharma (NASDAQ:COCP) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cocrystal Pharma GAAP EPS of -$0.19 beats by $0.02 [Seeking Alpha]Seeking Alpha
- Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsGlobeNewswire
COCP
Earnings
- 5/15/25 - Beat
COCP
Sec Filings
- 12/1/25 - Form 8-K
- 11/28/25 - Form 4
- 11/25/25 - Form 4
- COCP's page on the SEC website